Shafi Hasham

Hasham Shafi, PhD

Postdoctoral Associate

Office: CTS 314
Phone: 772-345-4731

Mansour Lab
Google Scholar Profile
ORCID Profile
FIU Discovery – updating soon…


With a Ph.D. in Pharmaceutics, Dr. Hasham Shafi’s research, conducted at CSIR-Central Drug Research Institute, India, and the Department of Pharmaceutical Sciences, University of Kashmir, India, primarily focuses on addressing challenges related to the poor solubility/bioavailability of drugs and engineering target-based drug delivery systems. Holding Bachelors and Master’s degrees in Pharmaceutical Sciences with specialization in Pharmaceutics from the University of Kashmir, Dr. Shafi’s journey includes three years of valuable experience as a Junior/Senior Research fellow at the Department of Nanotechnology (University of Kashmir) and the Department of Pharmaceutics (Birla Institute of Science and Technology). He is also a registered pharmacist at the Pharmacy Council of India.

As part of his Ph.D. fellowship program, Dr. Shafi investigated the co-delivery of DPIs of antibiofilm agents with antitubercular drugs to overcome drug-resistant pulmonary tuberculosis. His work delved into Mtb’s ability to form biofilms using various biomaterial matrices as a carbon source, resulting in impermeability to antitubercular drugs and contributing to drug resistance. Dr. Shafi successfully engineered a biofilm assay mimicking the in vivo mycobacterial biofilm niche to screen various biofilm-disrupting agents. In a collaborative doctoral research program, he explored the role of SOCS proteins in tuberculosis pathogenesis and investigated host-directed strategies using IFN-γ and calcitriol. Additionally, he contributed to research examining the potential of DPIs of pteromanid analogs as adjunct therapy in tuberculosis.

Expertise: Dr. Shafi’s expertise spans a diverse range of skills in formulation development, particularly dry powder inhalations (DPIs) and Fast Dissolving Delivery Systems. His proficiency includes analytical/bioanalytical method development for small molecules, characterization techniques, preclinical ADME, in vitro studies, microbiology, and in vivo studies, including those in BSL3 settings.

Research Interests

1. DPI as a targeted drug delivery approach.
2. Role of Biofilms in Drug-Resistant Tuberculosis.
3. Host-directed strategies for Tuberculosis.
4. Drug discovery
5. PK/PD
6. Fast dissolving drug delivery systems
7. Engineering Biomaterials
8. Physical Pharmaceutics

Recent Scholarly Works

  1. Optimizing the fabrication of electrospun nanofibers of prochlorperazine for enhanced dissolution and permeation properties. – Biomaterials Advances (2024)
  2. Transcriptional regulation of suppressors of cytokine signaling during infection with Mycobacterium tuberculosis in human THP-1-derived macrophages and in mice. – Microbes and Infection (2023)
  3. Super disintegrating oromucosal nanofiber patch of zolmitriptan for rapid delivery and efficient brain targeting. – Chemical Engineering Journal (2023)
  4. Preparation and Evaluation of Low-Dose Calcitriol Dry Powder Inhalation as Host-Directed Adjunct Therapy for Tuberculosis. – Pharmaceutical Research (2022)
  5. Transient transfection of the respiratory epithelium with gamma interferon for host-directed therapy in pulmonary tuberculosis. – Molecular Therapy-Nucleic Acids (2020)